AIM: Primary @entity628 ( @entity628 ) is a common cause of @entity1985 in adults. Most studies on @entity628 have combined pediatric and adult @entity1 . This study aims at assessing the response to immunosuppression and its impact on renal survival in adults with primary @entity628 . METHODS: @entity1 with @entity1985 with primary @entity628 seen from January 2010 to December 2014 were included. Clinical, laboratory and treatment details were recorded. @entity177 was defined as >= 50% decline in estimated glomerular filtration rate (eGFR) or progression to @entity454 . RESULTS: There were 116 @entity1 with median follow-up of 23.6 (6-65.1) months. Baseline @entity644 was 5.1    2.6 g/day and eGFR was 96.9    35.1 ml/min/1.73 m2. One hundred one (94.4%) @entity1 had received @entity7774 converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ @entity11882 ). One hundred fourteen @entity1 received @entity230 . Forty two of 114 @entity1 (36.8%)were @entity479 resistant. Thirty eight received calcineurin inhibitors (CNI). Seventeen (44.7%) were CNI resistant of which 2 achieved remission with alternate immunosuppression. Eleven (9.5%) @entity1 had worsening renal function - 9 had no remission, 2 had PR with none in CR (30 vs. 5.6% vs. 0, respectively, log-rank, p < 0.001). @entity63331 /ARBs use and remission of @entity644 were independently associated with better renal survival. CONCLUSION: Achieving remission, whether complete or partial, is the critical factor in predicting renal survival in nephrotic adults with primary @entity628 . @entity479 -resistant @entity1 have reasonable renal survival, if @entity644 is reduced with timely use of alternate immunosuppression. CNI resistance is a major hurdle in management with limited treatment options.

Primary @entity628 in XXXX Adults: Clinical Profile, Response to Immunosuppression and Outcome.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity7774 :: ('MESH:D000809', 'Chemical') :: ['angiotensin'] @entity628 :: ('MESH:D005923', 'Disease') :: ['focal segmental glomerulosclerosis', 'FSGS'] @entity177 :: ('MESH:D051437', 'Disease') :: ['Deterioration in renal function'] @entity63331 :: ('D000806', 'Chemical') :: ['ACEi'] @entity479 :: ('D013256', 'Chemical') :: ['steroid', 'Steroid'] @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic proteinuria'] @entity11882 :: ('OMIM:611809', 'Disease') :: ['ARB'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']
@entity1985 :: (MESH:D009404,Disease) :: ['Nephrotic']
